Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Abstract
Background: IL-17A is a founding member of the IL-17 family that has been implicated in the pathogenesis of inflammatory-associated diseases such as cancer and autoimmune disease. In cancer, IL-17A participates in many key events for tumor development, in part by affecting innate and adaptive immune system and also by direct modulation of many pro-tumor events. Moreover, IL-17A dysregulation at the site of inflammation is associated with rheumatoid arthritis, multiple sclerosis, psoriasis, among others. IL-17A has emerged as a topic of interest and is under profound investigation for its involvement in several types of inflammatory-associated diseases. Objective: This review aims to present an overview of the state of the art of IL-17A role in cancer and inflammation, as well as to describe recent patents targeting IL-17A with relevant clinical and biological properties for the prevention and treatment of cancer and inflammatory diseases. Methods: Relevant information was obtained by s...earching in PubMed using IL-17A or IL-17, cancer and inflammation as keywords, while relevant patents were obtained mainly from Google Patents. Results: Literature data indicated IL-17A as important biomolecule in the physiopathology of cancer and inflammatory diseases. Whereas, novel patents (2010 to 2017) targeting IL-17A are focused mainly on describing strategies to modulate IL-17A per se, co-modulation by bispecific antibodies to blocking IL-17A and important cytokines for IL-17A functions, upstream mechanisms and compounds to regulate IL-17A expression. Conclusion: The promising effects of patented agents against IL-17A may open new opportunities to therapeutic intervention targeting at different levels of involvement in the pathogenesis of cancer and inflammatory diseases.
Keywords:
Cancer / inflammation / interleukin-17A (IL-17A) / interleukin-17 Receptor A (IL-17RA) / patents / signaling / therapiesSource:
Recent Patents on Anti-Cancer Drug Discovery, 2018, 13, 2, 133-144Publisher:
- Bentham Science Publ Ltd, Sharjah
Funding / projects:
- UBO
- Phylogenetic anaysis and molecular evolution of highly variable viruses: coinfections, host-pathogene interactions (RS-175024)
- The pathogenetic mechanism in hematological malignancies (RS-175053)
DOI: 10.2174/1574892813666180220105958
ISSN: 1574-8928
PubMed: 29468982
WoS: 000432224500001
Scopus: 2-s2.0-85048982610
Collections
Institution/Community
Institut za medicinska istraživanjaTY - JOUR AU - Santibanez, Juan AU - Bjelica, Sunčica PY - 2018 UR - http://rimi.imi.bg.ac.rs/handle/123456789/892 AB - Background: IL-17A is a founding member of the IL-17 family that has been implicated in the pathogenesis of inflammatory-associated diseases such as cancer and autoimmune disease. In cancer, IL-17A participates in many key events for tumor development, in part by affecting innate and adaptive immune system and also by direct modulation of many pro-tumor events. Moreover, IL-17A dysregulation at the site of inflammation is associated with rheumatoid arthritis, multiple sclerosis, psoriasis, among others. IL-17A has emerged as a topic of interest and is under profound investigation for its involvement in several types of inflammatory-associated diseases. Objective: This review aims to present an overview of the state of the art of IL-17A role in cancer and inflammation, as well as to describe recent patents targeting IL-17A with relevant clinical and biological properties for the prevention and treatment of cancer and inflammatory diseases. Methods: Relevant information was obtained by searching in PubMed using IL-17A or IL-17, cancer and inflammation as keywords, while relevant patents were obtained mainly from Google Patents. Results: Literature data indicated IL-17A as important biomolecule in the physiopathology of cancer and inflammatory diseases. Whereas, novel patents (2010 to 2017) targeting IL-17A are focused mainly on describing strategies to modulate IL-17A per se, co-modulation by bispecific antibodies to blocking IL-17A and important cytokines for IL-17A functions, upstream mechanisms and compounds to regulate IL-17A expression. Conclusion: The promising effects of patented agents against IL-17A may open new opportunities to therapeutic intervention targeting at different levels of involvement in the pathogenesis of cancer and inflammatory diseases. PB - Bentham Science Publ Ltd, Sharjah T2 - Recent Patents on Anti-Cancer Drug Discovery T1 - Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation EP - 144 IS - 2 SP - 133 VL - 13 DO - 10.2174/1574892813666180220105958 ER -
@article{ author = "Santibanez, Juan and Bjelica, Sunčica", year = "2018", abstract = "Background: IL-17A is a founding member of the IL-17 family that has been implicated in the pathogenesis of inflammatory-associated diseases such as cancer and autoimmune disease. In cancer, IL-17A participates in many key events for tumor development, in part by affecting innate and adaptive immune system and also by direct modulation of many pro-tumor events. Moreover, IL-17A dysregulation at the site of inflammation is associated with rheumatoid arthritis, multiple sclerosis, psoriasis, among others. IL-17A has emerged as a topic of interest and is under profound investigation for its involvement in several types of inflammatory-associated diseases. Objective: This review aims to present an overview of the state of the art of IL-17A role in cancer and inflammation, as well as to describe recent patents targeting IL-17A with relevant clinical and biological properties for the prevention and treatment of cancer and inflammatory diseases. Methods: Relevant information was obtained by searching in PubMed using IL-17A or IL-17, cancer and inflammation as keywords, while relevant patents were obtained mainly from Google Patents. Results: Literature data indicated IL-17A as important biomolecule in the physiopathology of cancer and inflammatory diseases. Whereas, novel patents (2010 to 2017) targeting IL-17A are focused mainly on describing strategies to modulate IL-17A per se, co-modulation by bispecific antibodies to blocking IL-17A and important cytokines for IL-17A functions, upstream mechanisms and compounds to regulate IL-17A expression. Conclusion: The promising effects of patented agents against IL-17A may open new opportunities to therapeutic intervention targeting at different levels of involvement in the pathogenesis of cancer and inflammatory diseases.", publisher = "Bentham Science Publ Ltd, Sharjah", journal = "Recent Patents on Anti-Cancer Drug Discovery", title = "Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation", pages = "144-133", number = "2", volume = "13", doi = "10.2174/1574892813666180220105958" }
Santibanez, J.,& Bjelica, S.. (2018). Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation. in Recent Patents on Anti-Cancer Drug Discovery Bentham Science Publ Ltd, Sharjah., 13(2), 133-144. https://doi.org/10.2174/1574892813666180220105958 conv_4292
Santibanez J, Bjelica S. Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation. in Recent Patents on Anti-Cancer Drug Discovery. 2018;13(2):133-144. doi:10.2174/1574892813666180220105958 conv_4292 .
Santibanez, Juan, Bjelica, Sunčica, "Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation" in Recent Patents on Anti-Cancer Drug Discovery, 13, no. 2 (2018):133-144, https://doi.org/10.2174/1574892813666180220105958 ., conv_4292 .